Concepedia

Publication | Open Access

Pentostatin in Steroid-Refractory Acute Graft-Versus-Host Disease

DOIFull Paper Access

122

Citations

29

References

2005

Year

Javier Bolaños‐Meade, David A. Jacobsohn, Jeffrey Margolis, Adam Ogden, M. Guillaume Wientjes, John C. Byrd, David Lucas, Viki Anders, Michele Phelps, Michael R. Grever,
Journal of Clinical Oncology

Abstract

The suggested intravenous dose for a phase II study will be 1.5 mg/m2/d for 3 days. Pentostatin has activity in patients with steroid-refractory aGVHD that is worth exploring in future trials.

References

YearCitations

Page 1